EGFR-Mutated Lung Cancer Perspectives

In this video interview, Marina Garassino, MBBS, professor of medicine and director of the Thoracic Oncology Program at the University of Chicago, discussed:

• Highlights in EGFR-mutated lung cancer from ASCO 2021, including data on patritumab deruxtecan (HER3-DXd/U3-1402, Daiichi Sankyo) and combination amivantamab-lazertinib (Janssen);
• Results and impact of the ADAURA trial;
• How osimertinib (Tagrisso, AstraZeneca) and osimertinib-resistance has affected clinical practice;
• Strategies to help address resistance to tyrosine kinase inhibitors in EGFR-mutated NSCLC, including what to do if there’s presence of threonine at amino acid position 790 (T790M) mutation in patients taking first- and second- generation TKIs; and
• The greatest areas of unmet need in EGFR-mutated lung cancer.